CRDF
Price
$3.63
Change
-$0.14 (-3.71%)
Updated
May 17, 6:59 PM EST
82 days until earnings call
INM
Price
$0.29
Change
+$0.01 (+3.57%)
Updated
May 17, 6:59 PM EST
125 days until earnings call
Ad is loading...

CRDF vs INM

Header iconCRDF vs INM Comparison
Open Charts CRDF vs INMBanner chart's image
Cardiff Oncology
Price$3.63
Change-$0.14 (-3.71%)
Volume$288.49K
CapitalizationN/A
InMed Pharmaceuticals
Price$0.29
Change+$0.01 (+3.57%)
Volume$1.05M
CapitalizationN/A
View a ticker or compare two or three
CRDF vs INM Comparison Chart

Loading...

CRDFDaily Signal changed days agoGain/Loss if shorted
 
Show more...
INMDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
CRDF vs. INM commentary
May 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRDF is a StrongSell and INM is a StrongBuy.

COMPARISON
Comparison
May 18, 2024
Stock price -- (CRDF: $3.63 vs. INM: $0.29)
Brand notoriety: CRDF and INM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRDF: 50% vs. INM: 508%
Market capitalization -- CRDF: $162.35M vs. INM: $1.79M
CRDF [@Biotechnology] is valued at $162.35M. INM’s [@Biotechnology] market capitalization is $1.79M. The market cap for tickers in the [@Biotechnology] industry ranges from $593.52B to $0. The average market capitalization across the [@Biotechnology] industry is $2.75B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRDF’s FA Score shows that 0 FA rating(s) are green whileINM’s FA Score has 1 green FA rating(s).

  • CRDF’s FA Score: 0 green, 5 red.
  • INM’s FA Score: 1 green, 4 red.
According to our system of comparison, CRDF is a better buy in the long-term than INM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRDF’s TA Score shows that 6 TA indicator(s) are bullish while INM’s TA Score has 4 bullish TA indicator(s).

  • CRDF’s TA Score: 6 bullish, 4 bearish.
  • INM’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, CRDF is a better buy in the short-term than INM.

Price Growth

CRDF (@Biotechnology) experienced а +7.08% price change this week, while INM (@Biotechnology) price change was +12.04% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.41%. For the same industry, the average monthly price growth was +2.86%, and the average quarterly price growth was +60.72%.

Reported Earning Dates

CRDF is expected to report earnings on Aug 08, 2024.

INM is expected to report earnings on Sep 20, 2024.

Industries' Descriptions

@Biotechnology (+1.41% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for CRDF with price predictions.
OPEN
A.I.dvisor published
a Summary for INM with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
CRDF($162M) has a higher market cap than INM($1.79M). CRDF YTD gains are higher at: 145.270 vs. INM (-29.111).
CRDFINMCRDF / INM
Capitalization162M1.79M9,065%
EBITDAN/AN/A-
Gain YTD145.270-29.111-499%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
CRDF vs INM: Fundamental Ratings
CRDF
INM
OUTLOOK RATING
1..100
531
VALUATION
overvalued / fair valued / undervalued
1..100
66
Overvalued
27
Undervalued
PROFIT vs RISK RATING
1..100
97100
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
3580
P/E GROWTH RATING
1..100
10072
SEASONALITY SCORE
1..100
65n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

INM's Valuation (27) in the null industry is somewhat better than the same rating for CRDF (66). This means that INM’s stock grew somewhat faster than CRDF’s over the last 12 months.

CRDF's Profit vs Risk Rating (97) in the null industry is in the same range as INM (100). This means that CRDF’s stock grew similarly to INM’s over the last 12 months.

CRDF's SMR Rating (97) in the null industry is in the same range as INM (97). This means that CRDF’s stock grew similarly to INM’s over the last 12 months.

CRDF's Price Growth Rating (35) in the null industry is somewhat better than the same rating for INM (80). This means that CRDF’s stock grew somewhat faster than INM’s over the last 12 months.

INM's P/E Growth Rating (72) in the null industry is in the same range as CRDF (100). This means that INM’s stock grew similarly to CRDF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRDFINM
RSI
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
82%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
87%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
86%
MACD
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
79%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 5 days ago
87%
Bullish Trend 1 day ago
87%
Declines
ODDS (%)
Bearish Trend 10 days ago
89%
Bearish Trend 8 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
CRDFDaily Signal changed days agoGain/Loss if shorted
 
Show more...
INMDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SXTC1.150.07
+6.48%
China SXT Pharmaceuticals
EPAC37.710.12
+0.32%
Enerpac Tool Group Corp
SF82.93-0.13
-0.16%
Stifel Financial Corp
TELL0.52-0.01
-1.11%
Tellurian
ONCY1.11-0.02
-1.77%
Oncolytics Biotech

CRDF and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRDF has been loosely correlated with MDGL. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CRDF jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRDF
1D Price
Change %
CRDF100%
-2.94%
MDGL - CRDF
46%
Loosely correlated
+1.33%
ORMP - CRDF
39%
Loosely correlated
-1.29%
MNKD - CRDF
38%
Loosely correlated
N/A
CRSP - CRDF
36%
Loosely correlated
+0.99%
VRPX - CRDF
34%
Loosely correlated
-2.37%
More

INM and

Correlation & Price change

A.I.dvisor tells us that INM and VTYX have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that INM and VTYX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INM
1D Price
Change %
INM100%
+3.55%
VTYX - INM
31%
Poorly correlated
-5.02%
CRDF - INM
28%
Poorly correlated
-2.94%
PYPD - INM
28%
Poorly correlated
-2.82%
GLPG - INM
27%
Poorly correlated
+0.27%
CALC - INM
23%
Poorly correlated
+0.37%
More